Iterum Therapeutics Reports First Quarter 2020 Financial Results
14 mai 2020 06h45 HE
|
Iterum Therapeutics plc
--Phase 3 topline results from sulopenem clinical trials in uUTI and cUTI expected Q2 -- -- Raised $51.6 million through a private placement with new and existing investors -- DUBLIN,...
Iterum Therapeutics Provides Update on Phase 3 Clinical Trials of Sulopenem in Complicated Urinary Tract Infection (cUTI) and Uncomplicated Urinary Tract Infection (uUTI)
31 mars 2020 07h00 HE
|
Iterum Therapeutics plc
Topline results from uUTI and cUTI clinical trials to be announced in Q2 2020 Iterum Therapeutics maintaining business operations amid COVID-19 public health crisis DUBLIN, Ireland and CHICAGO,...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
12 mars 2020 06h45 HE
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection
26 déc. 2019 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral and IV Sulopenem in Complicated Urinary Tract Infection
18 nov. 2019 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports Third Quarter 2019 Financial Results and Highlights
12 nov. 2019 16h30 HE
|
Iterum Therapeutics plc
--Phase 3 topline data from the cIAI trial expected shortly-- --cUTI and uUTI Phase 3 trials remain on track to complete enrollment around year-end and report topline data in Q1 2020-- -- NDA...
Iterum Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
27 sept. 2019 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
14 août 2019 07h00 HE
|
Iterum Therapeutics plc
--Phase 3 Topline Data anticipated in the fourth quarter-- -- NDA filings expected in first quarter of 2020-- DUBLIN, Ireland and CHICAGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics to Present at the Canaccord Genuity 39th Annual Growth Conference
01 août 2019 07h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics to Present Data on Uncomplicated Urinary Tract Infections at ASM Microbe 2019
21 juin 2019 07h30 HE
|
Iterum Therapeutics plc
Limited options remain for successful empiric treatment of uncomplicated urinary tract infections (uUTIs) in the community DUBLIN, Ireland and CHICAGO, June 21, 2019 (GLOBE NEWSWIRE) -- Iterum...